NNI-351


NNI-351 is an active oral inhibitor of DYRK1A and a neurogenesis enhancer that is being developed by NeuroNascent, Inc. for the treatment of Down syndrome, depression and post-traumatic stress disorder (PTSD). [1] [2] Beginning in 2017, it is in the preclinical development phase and has not yet progressed in human clinical trials

Leave a Reply

Your email address will not be published. Required fields are marked *